Legis Daily

Right Rebate Act of 2019

USA116th CongressS-205| Senate 
| Updated: 1/24/2019
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (10)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Catherine Cortez Masto (Democratic)Amy Klobuchar (Democratic)Robert P. Casey (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Chuck Grassley (Republican)Richard Blumenthal (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Right Rebate Act of 2019 This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 24, 2019
Introduced in Senate
Jan 24, 2019
Read twice and referred to the Committee on Finance.
Jan 31, 2019

Latest Companion Bill Action

HR 116-937
Introduced in House
  • January 24, 2019
    Introduced in Senate


  • January 24, 2019
    Read twice and referred to the Committee on Finance.


  • January 31, 2019

    Latest Companion Bill Action

    HR 116-937
    Introduced in House

Health

Related Bills

  • HR 116-1839: Medicaid Services Investment and Accountability Act of 2019
  • HR 116-937: Right Rebate Act of 2019
Business recordsCivil actions and liabilityHome and outpatient careInflation and pricesMedicaidPrescription drugsState and local government operations

Right Rebate Act of 2019

USA116th CongressS-205| Senate 
| Updated: 1/24/2019
Right Rebate Act of 2019 This bill requires drug manufacturers with Medicaid rebate agreements for covered outpatient drugs to disclose drug product information. Manufacturers are subject to civil penalties for knowingly misclassifying drugs. Manufacturers are also required to compensate for rebates that were initially underpaid as a result of misclassification (whether or not such misclassification was committed knowingly).
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 24, 2019
Introduced in Senate
Jan 24, 2019
Read twice and referred to the Committee on Finance.
Jan 31, 2019

Latest Companion Bill Action

HR 116-937
Introduced in House
  • January 24, 2019
    Introduced in Senate


  • January 24, 2019
    Read twice and referred to the Committee on Finance.


  • January 31, 2019

    Latest Companion Bill Action

    HR 116-937
    Introduced in House
Ron Wyden

Ron Wyden

Democratic Senator

Oregon

Cosponsors (10)
Joni Ernst (Republican)Margaret Wood Hassan (Democratic)Catherine Cortez Masto (Democratic)Amy Klobuchar (Democratic)Robert P. Casey (Democratic)Debbie Stabenow (Democratic)Tina Smith (Democratic)Sherrod Brown (Democratic)Chuck Grassley (Republican)Richard Blumenthal (Democratic)

Finance Committee

Health

Related Bills

  • HR 116-1839: Medicaid Services Investment and Accountability Act of 2019
  • HR 116-937: Right Rebate Act of 2019
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCivil actions and liabilityHome and outpatient careInflation and pricesMedicaidPrescription drugsState and local government operations